DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT

BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Rob, Sheehan, Bart, Phillips, Patrick, Juszczak, Ed, Adams, Jessica, Baldwin, Ashley, Ballard, Clive, Banerjee, Sube, Barber, Bob, Bentham, Peter, Brown, Richard, Burns, Alistair, Dening, Tom, Findlay, David, Gray, Richard, Griffin, Mary, Holmes, Clive, Hughes, Alan, Jacoby, Robin, Johnson, Tony, Jones, Roy, Knapp, Martin, Lindesay, James, McKeith, Ian, McShane, Rupert, Macharouthu, Ajay, O'Brien, John, Onions, Caroline, Passmore, Peter, Raftery, James, Ritchie, Craig, Howard, Rob
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723100/
https://www.ncbi.nlm.nih.gov/pubmed/19630974
http://dx.doi.org/10.1186/1745-6215-10-57

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723100/
https://www.ncbi.nlm.nih.gov/pubmed/19630974
http://dx.doi.org/10.1186/1745-6215-10-57

Ejemplares similares